Scott Shively

Scott Shively is the current President and CEO of Bexion Pharmaceuticals. Prior to this, they were the CEO and Co-Founder of Neumentum, Inc., a non-opioid analgesic and neurology specialty pharmaceutical company. Scott has also served as the Senior Vice President and Chief Commercial Officer of Depomed, Inc. and Zogenix, Inc.

Scott has over 20 years of experience in the biotech and pharmaceutical industry, with a focus on pain and neurology. Scott has a proven track record in developing and commercializing innovative products with the potential to provide safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.

Scott is a world-class executive with extensive experience in drug development through commercialization. Scott is a visionary leader with a passion for improving patient outcomes. Under their guidance, Bexion Pharmaceuticals is making significant progress in developing new therapies for cancer and other rare diseases.

Scott Shively obtained a Bachelor’s Degree in Zoology and Chemistry from Duke University. Scott also holds a Bachelor of Science (B.S.) in Zoology from Duke University.

Some direct reports include Ray Takigiku - Founder & Chief Scientific Officer, Margaret Van Gilse - VP of Business Development, and Christy Rothwell - VP of Legal & Intellectual Property.